Use of a hspc117 molecule as rna ligase
AssigneeImba—Institut FüR Molekulare Biotechnologie GmbH
InventorsJohannes Popow, Stefan Weitzer, Javier Martinez, Karl Mechtler, Alexander Schleiffer
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of HSPC117 molecules as RNA ligase, methods of ligating RNA molecules, kits for these methods and uses and transgenic cells.
Claims17
The use of a HSPC117 molecule as RNA ligase, preferably for the transfer of a first RNA end to a second RNA end, in particular preferred wherein the first end comprises a 3′ phosphate, preferably a 2′,3′-cyclic phosphate, and/or wherein the second end comprises a 5′-OH terminus.
A kit suitable for performing RNA ligation, comprising
- a HSPC117 molecule,
- a RNA ligase reaction buffer comprising buffer components and one or more metal ions selected from Mg2+, Mn2+, Ni2+ or mixtures
- thereof, for use in a final concentration range of ca 0.1-20 mM, preferably 1-10 mM, in particular preferred 2-5 mM, optionally further comprising a RNA molecule with 2′,3′-cyclic phosphate, preferably further with a label.
A transgenic cell comprising an exogenously expressed HSPC117 molecule, preferably with an inducible promoter.
A HSPC117 knock-out cell or cell with reduced inhibited endogenous HSPC117 expression.
A method of reducing RNA ligase activity, in particular RNA>p ligase activity, in a cell comprising inhibiting a HSPC117 molecule in a cell, preferably by knock-out or RNAi.
A method of reducing tumor cell growth or a disease or infection dependent on host polymerases, such as hepatitis delta virus infection, comprising administering an HSPC117 molecule inhibitor to said cell, or of treating a disease in a subject associated with dysfunctional tRNA splicing, preferably pontocerebellar hypoplasia, comprising administering a HSPC117 molecule to said subject.
Dependencies are inferred from the claim text.